Actively Recruiting
Evaluating Nebulized Dexmedetomidine for Central Sensitization and Progression in Chronic Migraine Using Biomarkers and Neurophysiological Tests
Led by Beni-Suef University · Updated on 2026-08-17
146
Participants Needed
1
Research Sites
1 weeks
Total Duration
AI-Summary
What This Trial Is About
Chronic migraine is a neurological disorder marked by frequent headaches and heightened sensitivity to sensory inputs like light and sound. This trial evaluates nebulized dexmedetomidine, a drug that acts on specific receptors in the brain to reduce nerve excitability and inflammation related to migraine pain. The study focuses on how this treatment affects central sensitization and the progression of migraine using biomarkers and neurophysiological tests. Participants will be randomly assigned to receive either nebulized dexmedetomidine or a placebo normal saline through a jet nebulizer. The treatment is given three times per week for two weeks, with each dose containing dexmedetomidine at 1 microgram per kilogram in 4 mL saline. The study uses measures such as CGRP serum levels, nociceptive blink reflex, and trigeminal somatosensory evoked potentials to assess treatment effects on migraine pain pathways. During the study, participants will undergo assessments that include blood tests for CGRP levels and neurophysiological evaluations to monitor brainstem and cortical activity related to migraine. The primary outcome is the treatment effect on chronic migraine over six months. Safety and response to treatment will be closely monitored, with a total participation period lasting until the primary completion date in March 2027.
CONDITIONS
Brief Title
Effect of Nebulized Dexmedetomidine on Central Sensitization and Chronification in Migraine
Research Team
I
Ibthal Osama Fathy Ibrahim, MSc
W
Wael Fathy Hassan, Professor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here